Gilead Sciences, Inc. $GILD Shares Sold by Old North State Wealth Management LLC

Old North State Wealth Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,385 shares of the biopharmaceutical company’s stock after selling 4,182 shares during the quarter. Gilead Sciences makes up about 2.9% of Old North State Wealth Management LLC’s holdings, making the stock its 6th largest position. Old North State Wealth Management LLC’s holdings in Gilead Sciences were worth $6,191,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Invesco Ltd. increased its position in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Legal & General Group Plc increased its position in Gilead Sciences by 4.2% during the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after purchasing an additional 414,454 shares in the last quarter. Ameriprise Financial Inc. increased its position in Gilead Sciences by 5.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after purchasing an additional 400,002 shares in the last quarter. Nordea Investment Management AB increased its position in Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays assumed coverage on Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective for the company. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. Oppenheimer lifted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Mizuho lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Wells Fargo & Company lifted their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $156.42.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 0.0%

GILD opened at $139.03 on Monday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The stock has a market capitalization of $172.56 billion, a price-to-earnings ratio of 20.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.39. The business has a 50-day moving average of $145.13 and a two-hundred day moving average of $130.59. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.